West Nile Virus Detection in Urine by Tonry, Jessica H. et al.
West Nile Virus
Detection in Urine
Jessica H. Tonry,* Craig B. Brown,† 
Cecil B. Cropp,* Juliene K.G. Co,* 
Shannon N. Bennett,* Vivek R. Nerurkar,*
Timothy Kuberski,‡ and Duane J. Gubler*
We report West Nile virus (WNV) RNA in urine collect-
ed from a patient with encephalitis 8 days after symptom
onset. Viral RNA was detected by reverse
transcriptase–polymerase chain reaction (RT-PCR).
Sequence and phylogenetic analysis confirmed the PCR
product to have >99% similarity to the WNV strain NY
2000-crow3356.
W
est Nile virus (WNV) is a mosquitoborne flavivirus
in the Japanese encephalitis serocomplex of the
family Flaviviridae (1). Human disease is typically charac-
terized by a mild, self-resolving, denguelike illness with
the onset of fever and myalgia (2,3). In a small percentage
of patients, primarily the elderly and immunocompro-
mised, disease progresses to a more severe form with cen-
tral nervous system (CNS) involvement, including
encephalitis and meningitis (4,5). The death rate among
patients with neuroinvasive disease in recent epidemics
has averaged 10%. Among survivors, long-term neurolog-
ic sequelae may occur (6). Because WNV is a neurotropic
virus, its pathology in the CNS has been the focus of many
studies; therefore, little is known about WNV pathogene-
sis in organs other than the CNS. Studies of WNV in birds,
dogs, and rodents have shown that the kidney is a site of
replication (7–9); moreover, infectious WNV has been
recovered from urine samples from experimentally infect-
ed hamsters as early as day 1 to day 52 postinfection (9).
The purpose of this study was to determine whether WNV
is similarly shed in the urine of humans with WNV infec-
tions. To our knowledge, this report is the first of WNV
RNA detected in the urine of an infected patient with
encephalitis.
The Study
A65-year-old computer software engineer was admitted
to a hospital in Phoenix, Arizona, on July 7, 2004, with
fever, headache, and altered mental status evolving in the 7
days before admission. His cerebrospinal fluid (CSF) find-
ings were consistent with viral encephalitis: leukocyte
count 141 cells/mm3, 27% polymorphonuclear cells, 73%
lymphocytes; glucose 106 mg/L; protein 102 mg/L; and
abnormal electroencephalogram results. The patient was
treated empirically for 9 days with acyclovir, ribavirin, and
interferon  α-2B beginning on July 7, 2004. His fever
resolved, followed by gradual improvement in strength and
mental function. The patient recovered and was discharged.
CSF and serum samples were obtained on July 7 and
14, 2004. CSF tested positive for specific WNV
immunoglobulin (Ig) M antibodies by using a capture
enzyme-linked immunosorbent assay. Paired serum sam-
ples confirmed an acute WNV infection by showing a 4-
fold rise in titer from acute-phase (July 7 [day 8 of illness;
day of admission to hospital]) to convalescent-phase (July
14) sera on a 90% plaque reduction neutralization test
(PRNT) (10). Antibody titers for acute-phase and conva-
lescent-phase serum samples were 1:80 and >1:320,
respectively. PRNT tests were negative on urine samples
obtained on days 8 and 15 after symptom onset. CSF was
unavailable for PRNT and isolation.
Attempts at virus isolation, by using Vero cells (green
monkey kidney cells) and C6/36 cells (Aedes albopictus),
from urine samples collected on days 8, 11, 12, 13, 14,
and 15 after symptom onset were unsuccessful. Similarly,
we were unable to isolate virus from serum samples col-
lected on days 8 and 9 after symptom onset. Indirect
immunofluorescence assays used to confirm culture
results were negative.
RNA was extracted from 140 µL of freshly thawed
urine by using the QIAamp Viral RNA Mini Kit (Qiagen,
Valencia, CA, USA) according to manufacturer’s instruc-
tions. To detect specific WNVgene sequences, we used the
following primer sets: WNV 233, 640c and WNV 9483,
9794 that amplify the cap/prM gene and the NS5 gene
regions, respectively (11). To generate an amplicon we
used Qiagen One-Step RT-PCR Kit with the following
thermocycling conditions: reverse transcription (RT) at
50°C for 20 min, 94°C for 15 min, and 55°C for 30 s; 40
cycles of polymerase chain reaction (PCR) at 95°C for 10
s, 56°C for 10 s, and 72°C for 15 s. The urine sample col-
lected on day 8 of illness tested positive with the afore-
mentioned primer sets. The urine specimens analyzed by
RT-PCR on days 11, 12, 13, 14, and 15 tested consistently
negative with both primer sets.
Amplicons generated with primer set WNV 233, 640c
were purified by Qiagen Gel Purification Kit according to
the manufacturer’s instructions and sequenced on an auto-
mated sequencer (Model 373A, Applied Biosystems,
Foster City, CA, USA). Sequencing results based on the
capsid/prM region from the patient’s day 8 urine con-
firmed the identity of WNV Arizona JW 2004 (GenBank
accession no. DQ011267), which had 99.7% homology to
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no. AF404756.1) over the cap/prM region.
A phylogenetic tree was generated by comparing the
WNV Arizona JW 2004 sequence against 34 other WNV
strains by using a 356-bp sequence corresponding to
nucleotide positions 260–615 in the cap/prM region
(Figure). Previously published WNV isolates used in the
analysis included the first WNV isolate from Uganda in
1937 (GenBank accession no. M12294), the Egypt 1951
laboratory strain (Eg101, GenBank accession no.
AF260968), and several American isolates, such as the NY
2000-crow3356 isolate. After sequence alignment with
ClustalW, a phylogenetic tree was constructed by using a
maximum likelihood (ML) algorithm implemented in
PAUP* (v. 4.0b10, Sinauer Associates, Inc., Sunderland,
MA, USA). The ML tree was estimated by using the gen-
eral-time reversible (GTR+I) model of nucleotide substitu-
tion, with the substitution matrix, base composition, and
proportion of invariant sites (I) all estimated from the data.
For tree topology support, we performed 1,000 boot-
strapped neighbor-joining replicate trees under the ML
substitution model described above and also generated
posterior probabilities for each node by using Bayesian
MCMC (Metropolis-Hastings Markov chain Monte Carlo)
tree sampling (variable substitution rate by codon position,
4 chains of 2 × 106 generations sampled every 100 gener-
ations, burn-in of 2,000, and convergence assessed at
effective sample size [ESS] >400) implemented in
MrBayes v. 3 (12).
Four main geographic groupings are observed in the
phylogram. As expected, the WNV Arizona JW 2004
sequence grouped with the other isolates from the United
States. Isolates from Russia, Romania, France, and Italy
formed a distinct cluster, as did 3 Kunjin virus isolates and
their close relatives from China and Egypt (Figure). The
WNV 1937 Uganda sequence, along with other sequences
(lineage II), was characterized by having the longest
branch length (Figure), which implies poor homology with
the other isolates.
Contamination of samples within the laboratory is
highly improbable. First, the positive control used in all
tests was WNV strain Eg101, isolated from Egypt in 1951.
Sequence results of this control confirmed its identity and
showed 96.9% homology to the cap/PrM region. Second,
at the time of testing, our laboratory did not possess any
North American WNV isolates, including the WNV strain
NY 2000-crow3356, to which the WNVArizona JW 2004
sequence showed 99.7% homology. Finally, sample con-
tamination during RNAextraction and RT-PCR procedures
was unlikely because we used a continuous single-sample
RNA extraction, and RT-PCR was accompanied by a neg-
ative water control. Results from the continuous single-
sample test confirmed previous results: the patient’s urine
on day 8 after symptom onset tested positive for WNV
RNA by RT-PCR, and the water control was negative. No
blood was visible in the day 8 urine sample. A contempo-
raneous serum sample collected on day 8 was negative by
both RT-PCR and virus isolation.
Conclusions
This report is the first of WNV RNA detected in urine
from a patient with encephalitis. St. Louis encephalitis
virus (SLEV), a related neurotropic flavivirus, has been
reported in human urine. SLEV antigen was detected by
indirect immunofluorescence, electron microscopy, and
immune electron microscopy in 12 patients during the
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Figure. Maximum likelihood (ML) tree showing the phylogenetic
relationships between West Nile virus (WNV) urine sample Arizona
JW 2004 (italicized and underlined) and previously published
WNV strains based on capsid/prM gene junction (356 bp).
Samples are coded by location, strain, and year of isolation.
Locations include France (FR); Kunjin (Kunj); Romania (Rom);
Russia (Russ); Tunisia (Tun); Uganda (Ugda); Volgograd, Russia
(Vlgd); and the US states of New York (NY), Texas (TX), New
Jersey (NJ), Maryland (MD), and Connecticut (CN). Support indi-
cated above and below nodes are bootstrap values (1,000 neigh-
bor-joining replicates using the ML model of evolution) and
Bayesian posterior probabilities (Bayesian MCMC [Metropolis-
Hastings Markov chain Monte Carlo tree sampling] for 4 chains
length 2 × 106, sample frequency 100, with a 2,000-tree burn-in),
respectively.1976 outbreak in the United States (13). Furthermore,
experimental animal studies have shown that certain fla-
viviruses are shed in the urine. A study on Japanese
encephalitis virus infection in a mouse model showed viral
shedding in urine; however, viral shedding did not neces-
sarily correlate with isolation of virus from the kidney
(14). In a recent study, infectious WNV was isolated from
hamster urine 52 days after initial infection despite the
development of high antibody titers against WNV (9).
Based on the above reports on flavivirus shedding in
humans and experimental animals and our detection of
WNV RNAin human urine, we believe WNV may be shed
in human urine during the course of infection.
A rapid diagnostic test for flaviviral infection in
humans is of clinical interest. Historically, flavivirus infec-
tions have been diagnosed by serologic tests or virus isola-
tion (15). Several molecular techniques are available for
diagnosis (11), but these tests are not readily accessible in
many community medical facilities where disease is com-
monly reported. We believe the development of a rapid
diagnostic test for human flaviviral infections is warranted.
The implications of our finding remain unclear. The
presence of WNV RNA in the day 8 urine sample but not
subsequent urine samples suggests that neutralizing anti-
bodies in the blood may prevent virus excretion in the
urine. WNV would likely be excreted in urine during the
viremic phase of illness. Thus, future studies on WNV in
human urine should emphasize early collection and test-
ing. In addition, the effect of interferon and ribavirin on the
recovery of WNV from the urine remains unknown.
Studies currently under way will provide additional infor-
mation on how often and for how long WNV can be found
in urine samples from patients with clinical and subclinical
WNV infections.
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